Clinical Trials Browser

Phase 1/2 × Lung Neoplasms × trametinib × Clear all

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03076164 2024-04-02

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Phase 1/2 Completed

24 enrolled 8 charts

Adenocarcinoma of Lung, Lung Neoplasms